What Is a Bispecific Antibody? — A Simple Guide for Lymphoma Patients

 

The clouds that day looked like two birds facing each other — I didn't notice until later

 

What Is a Bispecific Antibody?

If you have been reading about newer lymphoma treatments recently, you have probably come across this term.

 

Bispecific antibody.

 

It shows up in articles about Lunsumio. It shows up in articles about Epcoritamab. It is becoming one of the most important concepts in lymphoma treatment right now — and once you understand how it works, a lot of things start to make sense.

 

This post is a simple explanation. No medical background needed.

 

First: How Did Traditional Treatments Work?

Let's use Rituximab as an example — one of the most widely used lymphoma drugs for decades.

 

Rituximab targets one thing: CD20, a protein on the surface of lymphoma cells. It locks onto that target and either kills the cancer cell directly, or flags it so the immune system can find and destroy it.

 

Effective — but limited.

 

Cancer cells are adaptable. Over time, some lymphoma cells reduce or eliminate their CD20 expression. When that happens, Rituximab has nothing to attach to. The drug stops working. This is how resistance develops.

 

So What Does a Bispecific Antibody Do Differently?

The name tells you everything.

 

Bi — two.

Specific — targets.

 

A bispecific antibody grabs two things at the same time.

 

One hand holds onto the cancer cell (CD20).

The other hand holds onto a T cell — your own immune cell (CD3).

 

It physically brings them together. Forces them into contact. The T cell, now face to face with the cancer cell, recognizes it as a threat and destroys it directly.

 

A simple way to think about it:

Traditional antibody: "There's a cancer cell over there. Immune system — go find it."
Bispecific antibody: "Immune system — I'm bringing you right to the cancer cell. Now."

 

More direct. More immediate. And because it works through a completely different mechanism than traditional chemotherapy or anti-CD20 antibodies, it can be effective even when previous treatments have stopped working.

 

Why Does This Matter for Follicular Lymphoma?

Follicular Lymphoma has a pattern: remission, relapse, repeat. Each time the disease comes back, previous treatments have less effect. Options narrow.

 

Bispecific antibodies offer something genuinely new — a different mechanism that does not rely on the same pathways that previous treatments used. For relapsed and refractory patients, that is significant.

 

There is also a numbers issue worth understanding.

 

Follicular Lymphoma accounts for around 5% of non-Hodgkin lymphoma cases in Korea — roughly 300 new patients per year. In Western countries, that figure is closer to 20%. Because the patient population in Korea is small, drug development, approval, and insurance coverage move more slowly than for more common lymphoma types. Every new treatment option matters more when there are fewer of them.

 

Bispecific Antibodies Approved for Follicular Lymphoma

Currently, two bispecific antibodies have been approved for Follicular Lymphoma:

 

① Mosunetuzumab (Lunsumio)

CD20 × CD3 bispecific antibody.

Used as monotherapy in relapsed or refractory Follicular Lymphoma.

Korea MFDS approval: November 2023

Insurance coverage in Korea: not currently covered

 

→ Full post: [Lunsumio(Mosunetuzumab): What I Learned Researching My Own Next Treatment] 

 

② Epcoritamab (Epkinly)

Also a CD20 × CD3 bispecific antibody.

Korea approval status: under review

US and EU: approved

 

→ Full post: [Epcoritamab (Epkinly) A New Treatment Option for Relapsed Follicular Lymphoma]

 

A Note on DLBCL

Bispecific antibodies are also being used in Diffuse Large B-Cell Lymphoma (DLBCL) — a more common lymphoma type with over 10,000 new cases per year in Korea.

 

Epcoritamab received Korean MFDS approval for DLBCL in June 2024, with insurance coverage beginning April 2026. Glofitamab is also in use.

 

The gap is worth noting: the same class of drug, available and covered for DLBCL patients, while Follicular Lymphoma patients wait. That is the reality of being in a smaller patient population.

 

Where I Am in This

I am a Stage 4 Follicular Lymphoma, Grade 3A patient on my second relapse. Mosunetuzumab is my next planned treatment.

 

Understanding how these drugs work — really understanding, not just the name — matters to me. I hope this post helps it matter to you too.

---

This post is a summary of publicly available information and does not constitute medical advice. Please consult your oncologist for all treatment decisions.